Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsInsulin glargine

    Insulin Glargine

    Jump to

    • Plan to enter EU market with Insulin Glargine in second half of the year: Biocon

      We are now ready to enter the European market with our Insulin Glargine as a biosimilar, in the second half of this year, said Kiran Mazumdar Shaw, CMD, Biocon.

    • Biosimilars to lead growth; generics to be a small part: Biocon

      Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.

    • Biocon to launch insulin glargine in Malaysia in H2 FY17

      The biosimilar product, which is developed and manufactured by Biocon, has already been launched by its partner Fujifilm Pharma Co in Japan earlier this month.

    • Biocon surges 4%, launches diabetic drug in Japan

      The company's partner FUJIFILM Pharma has launched Insulin Glargine in Japan, for which it had received Japanese regulator approval in last quarter.

    • Biocon jumps 5% on Japan approval for insulin Glargine

      "Ministry of Health, Labour and Welfare (MHLW) of Japan has approved its biosimilar insulin Glargine," says the company in its filing.

    • Biocon jumps 3% on Mexican nod for insulin glargine

      Shares of Biocon gained 3 percent intraday Friday on getting approval from the Mexican health authority for its insulin glargine.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347